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Abstract 
Like other eukaryotic organisms, Toxoplasma gondii promoters feature both constitutive 
and life-stage regulated cis-elements. Using a transcriptomic microarray approach, a 
cluster of transcripts upregulated early during bradyzoite differentiation was identified. 
Computational analysis of the promoter regions of these “up-early” transcripts identified 
a shared upstream consensus motif, a putative transcription factor binding site. Using a 
dual luciferase assay adapted for recombinational cloning and reporter gene 
quantification by qPCR, we demonstrate developmental stage-specific expression of the 
luciferase reporter gene inserted downstream of the transcription factor binding site. 
The shared consensus motif was found to be an autonomous cis-element by conversion 
of a constitutive promoter into a bradyzoite growth condition-inducible promoter. A gel-
shift experiment showed the cis-element’s binding to bradyzoite nuclear proteins. Mass 
spectrometry of the shifted gel band identified a protein possessing an apicomplexan 
AP2 transcription factor domain. Much detail concerning the mechanism of 
differentiation is yet to be discovered and this work highlights the mediation of life cycle 
progression by bradyzoite differential gene expression. Taken together, these data 
demonstrate the control an early bradyzoite promoter element exercises on stage 
differentiation.  
 
Key Words: bradyzoite differentiation, gene regulation, gene expression, Toxoplasma 
gondii 
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Introduction 
Toxoplasma gondii is a single-celled, obligate intracellular parasite with a worldwide 
distribution, chronically infecting one third of the world’s population [1,2]. This 
apicomplexan pathogen is capable of infecting all nucleated mammalian cells, and is 
the etiologic agent of toxoplasmosis in humans [3]. Recrudescence of the chronic 
infection in immunocompromised patients (e.g. AIDS, cancer, and organ transplant 
patients) can cause fatal encephalitis [4,5]. Additionally, primary infection in otherwise 
healthy pregnant women can cause severe birth defects or spontaneous abortion of the 
fetus [6,7]. The wide distribution and significant public health impact of T. gondii 
highlight the critical need to further characterize the basic biology of this important 
parasite to discover novel biomedical solutions to it. 
The T. gondii developmental cycle includes the conversion from tachyzoite to bradyzoite 
– stages which give rise to acute and chronic infection, respectively [8]. While 
prophylaxis for acute infection with tachyzoites is available [9] and many promising 
experimental compounds are in development [10,11], the cyst-forming bradyzoite stage 
has no treatment or cure. Many apicomplexan transcriptome analyses have focused on 
developmental gene expression, as shown in the variety of microarray and RNA-Seq 
datasets investigating developmental stages found in the ToxoDB, PlasmoDB, and 
CryptoDB genomics resources [12–14]. Analyses of apicomplexan transcriptomes have 
shown differential expression of transcripts accompanying the progression of the 
parasite through life-cycle stages [15–17]. This is particularly true of Plasmodium, as 
staged transcription is observed in a large portion of mRNAs with limited shared 
expression among the life stages [18]. In T. gondii, serial analysis of gene expression 
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(SAGE) tags have been used to characterize the pool of transcripts expressed through 
development; it was shown that mRNAs which are stage-specific accounted for 18% of 
all SAGE tags identified [17]. The stage-specific nature of large subsets of 
apicomplexan transcripts as shown by microarray, RNA-Seq, and SAGE analyses lends 
support to the idea that apicomplexan development is, in part, driven by the ordered 
activation of the appropriate transcript subsets which correspond to the life stage being 
transitioned to. It appears that regulation at transcription initiation is a major mechanism 
by which gene expression is controlled in apicomplexans. 
In this work, we utilize a bradyzoite differentiation time series microarray dataset to 
identify a cluster of transcripts upregulated early during bradyzoite differentiation and 
use a computational analysis to extract a shared, consensus DNA motif from their 
promoter regions – a putative transcription factor binding site. An apicomplexan Apetala 
2 (AP2)-domain transcription factor is predicted to bind the identified motif by mass 
spectrometry analysis followed by peptide mass fingerprinting. It is further shown by a 
dual luciferase model adapted for recombinational cloning and quantitative PCR that 
this motif acts as an autonomous cis-element which regulates the expression of 
bradyzoite-specific transcripts and can convert a constitutive promoter into one which is 
chronic stage-specific. 
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Materials and Methods 
Cell culture. The Type II Prugniaud (Pru) strain shows robust bradyzoite differentiation 
and PruΔku80Δhxgprt was used to generate the transient transgenic strains. This strain 
was maintained by serial passage into confluent human foreskin fibroblast (HFF) 
monolayers cultured in D10 media containing Dulbecco’s modified Eagle’s medium 
(DMEM), 10% (v/v) fetal bovine serum, 2 mM L-alanyl-L-glutamine, 100 U/mL Penicillin, 
100 µg/mL Streptomycin, and 20 µg/mL Gentamicin at 37 °C with 5% CO2. Bradyzoite 
induction was accomplished by growth in capped flasks with CO2-depleted alkaline 
media containing Eagle’s minimum essential medium (MEM), 1% (v/v) dialyzed fetal 
bovine serum, 25 mM HEPES solution, 2 mM L-alanyl-L-glutamine, 100 U/mL Penicillin, 
100 µg/mL Streptomycin, and 25 µg/mL Gentamicin adjusted to pH 8.2 with NaOH. 
Promoter constructs. The Dest-p-firefly destination vector which carries the cassette B 
fragment (containing the ccdB toxic and chloramphenicol resistance markers) upstream 
of the firefly luciferase coding region was used for Gateway™ recombinational cloning. 
The Dest-p-renilla-α-tubulin was used as a transfection efficiency control, and both 
described plasmids were generous gifts from Michael White [19]. Promoter fragments of 
the well-documented, constitutive dihydrofolate reductase-thymidylate synthase (DHFR-
TS) gene [20] were designed to include the 5’-upstream genomic sequence, flanking 
attB sites, and the translational start site, designed such that the attB2 sequence would 
be translated in frame with the firefly luciferase CDS. These fragments were ordered as 
double-stranded gBlocks® Gene Fragments (Invitrogen). Promoter fragments were first 
cloned into the pDONR221 entry vector (Invitrogen) by an 18-hr incubation with the 
Gateway® BP Clonase™ II Enzyme (Invitrogen) to produce modified pDONR221 entry 
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clones. Following verification by Sanger sequencing, the promoter fragment from each 
entry clone was cloned into the Dest-p-firefly destination vector by an 18-hr incubation 
with the Gateway® LR Clonase™ II Enzyme (Invitrogen) to yield destination clones. The 
destination clones were also verified by Sanger sequencing to ensure successful 
recombination and correct orientation. Plasmids featuring the ccdB toxic marker (Dest-
p-firefly and pDONR221) were maintained in One Shot® ccdB Survival™ 2 T1R 
Escherichia coli cells (Invitrogen), and all other vectors were maintained in 10-beta E. 
coli cells (NEB). 
Dual Luciferase Assay by Quantitative PCR. PruΔku80Δhxgprt strain parasites were 
electroporated according to an amended protocol described previously [3,21] with 50 µg 
each of a promoter construct destination clone and the control Dest-p-renilla-α-tubulin 
plasmid. Transfections were performed in duplicate and each sample was transferred 
into one T25 cm2 flask each (one each for tachyzoite and bradyzoite growth conditions) 
and allowed to recover for 12 h at 37 °C with 5% CO2. After ~24 h, one flask was 
selected for bradyzoite induction by shifting to alkaline (pH 8.2), CO2-depleted media.  
To assay the level of transcription early in bradyzoite differentiation, infected 
monolayers were Dounce homogenized, filtered, and parasite RNA was isolated 16 h-
post induction from both tachyzoite and bradyzoite flasks with RNeasy Plus Mini 
reagents (Qiagen) and cDNA was produced from mRNAs with Maxima reverse 
transcriptase (Thermo Scientific) and a poly(T) primer according to manufacturers’ 
instructions. Quantitative PCR was used to measure transcript abundance of the dual 
luciferases and a constitutively-expressed housekeeping gene (histone H2B variant 
TGME49_009910) for each transfected life stage, using the primers listed in 
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Supplemental Table 1. Synthesized cDNA was mixed with the Luminaris HiGreen qPCR 
Master Mix (ThermoFisher Scientific) and the qPCR reactions were performed in 
triplicate for each promoter construct at 50 ˚C for 2 min, 95 ˚C for 10 min, and 40 cycles 
of 95 ˚C for 15 sec, 60 ˚C for 30 sec, and 72 ˚C for 30 sec. Reaction specificity was 
assayed by melt curve analysis.  
Relative quantification of transcript abundance was calculated using the ΔΔCt method 
[22], experiments were conducted on a Rotor-Gene Q 5plex HRM Platform (Qiagen), 
and data was processed using the Rotor-Gene Q Series software v2.3.1 (Qiagen). Fold 
expression of both firefly and renilla luciferase in both tachyzoites and bradyzoites were 
normalized to histone H2B variant expression; fold expression of firefly luciferase was 
then normalized to renilla levels by comparing the ratio of the firefly promoter construct 
expression to that of the α-tubulin-renilla promoter construct. 
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Results 
Induction of Bradyzoite-specific Expression by the DNA Motif. 
Previous work included microarray analysis of T. gondii expression in a 48-hour time 
course identified subsets of transcripts expressed at distinct timepoints during 
bradyzoite induction. A consensus DNA motif was also identified computationally in the 
promoters of 71 early-expression genes. The DNA motif was examined to assess 
whether it was an autonomous-acting cis-element by inserting the motif into a weak 
promoter upstream of the firefly luciferase reporter gene. DHFR-TS is known to be a 
constitutive, weakly-expressed transcript; the constitutive expression of this gene 
regardless of growth stage has been confirmed by microarray both by the dataset 
detailed in this study and by others (M.S. Behnke and M.W. White, ToxoDB). The 1000 
bp genomic fragment 5’ of the DHFR-TS gene [23] was selected for this experiment.  
The native DHFR-TS promoter and the promoter with three copies of the pyrimidine-rich 
DNA motif inserted 100 bp upstream of the major transcriptional start site at -369 bp 
[23] were designed and ordered as described (sequences are given in Supplemental 
Table 2). A promoter with three scrambled copies of the DNA motif was also designed 
to confirm that any observed impact on expression during bradyzoite induction was not 
sequence-specific and not simply an artefact of adding a pyrimidine-rich sequence or 
disrupting a repressor site. A diagram of the three promoter constructs cloned into Dest-
p-firefly destination vectors is shown in Figure 1. The introduction of the DNA motif cis-
element, but not the native or scrambled cis-elements, led to upregulation of the target 
gene in bradyzoite conditions. (Figure 2). This conversion was also seen to be specific 
to the period of early induction; following 7 days of induction, parasites transfected with 
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the construct with three copies of the DNA motif showed no significant difference in 
luciferase expression between tachyzoite and bradyzoite populations (data not shown). 
This data indicates that the identified DNA motif is autonomous, i.e., is sufficient to 
effect an increase in gene expression during bradyzoite induction.  
 
  
Figure 1. Diagram of Promoter Constructs. The three promoter constructs used in 
this study were designed and ordered as gBlocks™ from Invitrogen with attB1 and attB2 
sites flanking them, corresponding to the attP1 and attP2 sites on the Dest-p-firefly 
destination vector. 
The DHFR-TS promoter (-1000 bp) was modified to contain three copies of either the 
putative motif or scrambled versions of the motif, placed 100 bp 5’ of the major 
transcriptional start site (TSS). Each promoter construct was inserted into the 
destination vector by recombinational cloning, immediately upstream of the firefly 
luciferase coding region. 
11 
 
 
 
Figure 2. Induction of Expression During Bradyzoite Differentiation by the DNA 
Motif. The PruΔku80Δhxgprt strain was transiently transfected in duplicate and 
bradyzoite-condition flasks were induced for 16 h by pH 8.2, CO2-depleted media. 
Parasites were separated by homogenization and filtration, RNA was isolated, and 
quantitative PCR was performed in triplicate to assay the transcription of the dual 
luciferases and a housekeeping gene. Results of both luciferases were normalized to 
histone H2B variant and are reported as the fold expression of firefly luciferase relative 
to that of renilla luciferase driven by the α-tubulin promoter. No change in luciferase 
expression was observed in the tachyzoite stage for any of the constructs. In contrast, 
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induced parasites showed a marked increase in luciferase transcription in the construct 
with three copies of the DNA motif cis-element compared to the wild-type DHFR-TS 
promoter. 
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Discussion 
Utilizing the dual luciferase assay and alkaline bradyzoite induction models, we show 
that a putative transcription factor binding site identified in the 5’ promoter regions of a 
cluster of transcripts upregulated early during T. gondii bradyzoite differentiation is able 
to induce luciferase transcription under alkaline bradyzoite induction. This cis-element 
was identified as autonomous by its ability to induce greater expression during 
bradyzoite differentiation following insertion into the constitutive DHFR-TS promoter 
(Figure 2). A protein binding assay demonstrated the site-specific binding of nuclear 
proteins to this cis-element (previous data not shown), and mass spectrometry followed 
by computational analysis identified a small group of proteins predicted to bind the 
consensus DNA motif. These results confirm the concept that a major control 
mechanism of apicomplexan development is transcriptional initiation and this study is 
the first to examine the control of transcriptionally-active mRNAs which are specifically 
upregulated early in bradyzoite differentiation. 
The transcription factor which bound to the DNA motif was identified as the 
apicomplexan AP2-domain transcription factor, AP2III-3. The AP2 transcription factors 
are a well-documented family of transcription factors which have been implicated in 
stage-specific transcription [24–28]. While AP2III-3 has been identified in the literature 
as being upregulated ~200-fold during bradyzoite differentiation [27], it has otherwise 
not been characterized in the literature. It is conceivable that because this transcription 
factor activates the transcription of such a large subset of bradyzoite-initiating proteins, 
it is necessary for bradyzoite differentiation and cyst development. This expression 
analysis work will continue with a knock-out of AP2III-3 to examine whether the gene 
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knock-out impacts T. gondii’s ability to differentiate into the bradyzoite stage. If it is 
shown that deletion of this gene removes or severely inhibits T. gondii bradyzoite 
formation, thus reducing risk of chronic infection, an excellent live vaccine candidate 
strain will have been identified. Considering the serious public health issues that 
accompany lifelong chronic infection in immunocompromised individuals, the production 
of an efficacious vaccine is paramount. 
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Supplemental Data 
Primer 
# 
Primer 
Name 
Amplicon and 
Direction 
Sequence (5’ to 3’) 
BB09 qRen2-F 
Renilla luciferase 
forward 
GGGTGCTTGTTTGGCATTTCA 
BB10 qRen2-R 
Renilla luciferase 
reverse 
GGCAACATGGTTTCCACGAAG 
BB19 qLuc4-F 
Firefly luciferase 
forward 
CGTTCGGTTGGCAGAAGCTA 
BB20 qLuc4-R 
Firefly luciferase 
reverse 
CACTACGGTAGGCTGCGAAA 
BB33 qHis2b-F 
Histone H2B variant 
forward 
GCTTGGCTGATGAAGCAGTTCGTT 
BB34 qHis2b-R 
Histone H2B variant 
reverse 
AGTCGTGTACTTGGTCACTGCCTT 
 
Table S1. Oligonucleotides used for quantitative PCR. The qPCR reactions were 
performed using the described primers. To ensure specificity of the luciferase primer 
pairs, that is, having no T. gondii or human host cell targets, qPCR was also run on a 
mock transfected strain and the absence of either luciferase amplicon was confirmed. 
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Promoter 
Construct 
Sequence (5’ to 3’) 
Native 
DHFR-TS 
-1000 bp 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGTGCCACGACTTCTAAATCCGGCGACAGGC
TGGTCTTTTGTCTTACCACGTATTAGCCCGCGTGCGGATTTCTCGGAGCGCACCTGTTCAACA
CTAGAAAACGGAGTTTCCTGATCGAGAAGCCACCACCTTTCCAGAAGTTGAACGCTAGCATGT
CATTCGATTTTCACCCCCCGCGTAGTTCCTGTGTGTCATTCGTTGTCGAGACAACTCTGTCCC
GCCCCGGTGCTGTTCCATATGCGTGACTTTCCCGCAATTTTTTCAGACTTTCAGGAAAGACAG
GCTCCGGAACGATCTCGTCCATGACTGGTAAATCCACGACACCGCAATGGCCCCCAGCACCT
CTATCTCTCGTGCCAGGGGACTAACGTTGTATGCGTCTGCGTCTTGTCTTTTTGCATTCGCTTT
CCAAAAAAGAGAGCCATCCGTTCCCCCGCACATTCAACGCCGCGAGTGCGGTTTTTGTCTTTT
TTGAGTGGTAGGACGCTTTTCATGCGCGAACTACGTGGACATTAAGTTCCATTCTCTTTTTCGA
CAGCACGAAACCTTGCATTCAAACCCGCCCGGGGAAGATCCGATCTTGCTGCTGTTCGCAGT
CCCAGTAGCGTCCTGTCGGCCGCGCCGTCTCTGTTGGTGGGCAGCCGCTACACCTGTTATCT
GACTGCCGTGCGCGAAAATGACGCCATTTTTGGGAAAATCGGGGAACTTCATTCTTTAAAAGT 
ATGCGGAGGTTTCCTTTTTCTTCTGTTCGTTTCTTTTTCTCGGGTTTGATAACCGTGTTCGATG
TAAGCACTTTCCGTCTCTCCTCCGTGCTTTGTTCGACATCGAGACCAGGTGTGCAGATCCTTC
GCTTGTTGATCCGGAGACGCGTGTCTCGTAGAACCTTTTCATTTTACCACACGGCAGTGCTGA
GCACTGCTCTGAGTGCAGCAGGGACGGGTGAAGTTTCGCTTTAGTAGTGCGTTTCTGCTCTA
CGGGGCGTTGTCGTGTCTGGGAAGATGGCGGACCCAGCTTTCTTGTACAAAGTGGTGGGG 
DHFR-TS  
-1000 bp 
with DNA 
Motif 3x  
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGTGCCACGACTTCTAAATCCGGCGACAGGC
TGGTCTTTTGTCTTACCACGTATTAGCCCGCGTGCGGATTTCTCGGAGCGCACCTGTTCAACA
CTAGAAAACGGAGTTTCCTGATCGAGAAGCCACCACCTTTCCAGAAGTTGAACGCTAGCATGT
CATTCGATTTTCACCCCCCGCGTAGTTCCTGTGTGTCATTCGTTGTCGAGACAACTCTGTCCC
GCCCCGGTGCTGTTCCATATGCGTGACTTTCCCGCAATTTTTTCAGACTTTCAGGAAAGACAG
GCTCCGGAACGATCTCGTCCATGACTGGTAAATCCACGACACCGCAATGGCCCCCAGCACCT
CTATCTCTCGTGCCAGGGGACTAACGTTGTATGCGTCTGCGTCTTGTCTTTTTGCATTCGCTTT
CCAAAAAAGAGAGCCATCCGTTCCCCCGCACATTCAACGCCGCGAGTGCGGTTTTTGTCTTTT
TTGAGTGGTAGGACGCTTTTCATGCGCGAACTACGTGGACATTAAGTTCCATTCTCTTCTCTCT
TCTTCTCTCTTCCTTCTTTACTAGTCCTACTCTCTTCTTCTCTCTTCCTTCTTTTCGATGAGACG
CTCTCTTCTTCTCTCTTCCTTCTTTTTTCGACAGCACGAAACCTTGCATTCAAACCCGCCCGGG
GAAGATCCGATCTTGCTGCTGTTCGCAGTCCCAGTAGCGTCCTGTCGGCCGCGCCGTCTCTG
21 
 
TTGGTGGGCAGCCGCTACACCTGTTATCTGACTGCCGTGCGCGAAAATGACGCCATTTTTGG
GAAAATCGGGGAACTTCATTCTTTAAAAGTATGCGGAGGTTTCCTTTTTCTTCTGTTCGTTTCT
TTTTCTCGGGTTTGATAACCGTGTTCGATGTAAGCACTTTCCGTCTCTCCTCCGTGCTTTGTTC
GACATCGAGACCAGGTGTGCAGATCCTTCGCTTGTTGATCCGGAGACGCGTGTCTCGTAGAA
CCTTTTCATTTTACCACACGGCAGTGCTGAGCACTGCTCTGAGTGCAGCAGGGACGGGTGAA
GTTTCGCTTTAGTAGTGCGTTTCTGCTCTACGGGGCGTTGTCGTGTCTGGGAAGATGGCGGA
CCCAGCTTTCTTGTACAAAGTGGTGGGG 
DHFR-TS 
 -1000 bp 
with 
Scrambled 
Motif 3x  
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGTGCCACGACTTCTAAATCCGGCGACAGGC
TGGTCTTTTGTCTTACCACGTATTAGCCCGCGTGCGGATTTCTCGGAGCGCACCTGTTCAACA
CTAGAAAACGGAGTTTCCTGATCGAGAAGCCACCACCTTTCCAGAAGTTGAACGCTAGCATGT
CATTCGATTTTCACCCCCCGCGTAGTTCCTGTGTGTCATTCGTTGTCGAGACAACTCTGTCCC
GCCCCGGTGCTGTTCCATATGCGTGACTTTCCCGCAATTTTTTCAGACTTTCAGGAAAGACAG
GCTCCGGAACGATCTCGTCCATGACTGGTAAATCCACGACACCGCAATGGCCCCCAGCACCT
CTATCTCTCGTGCCAGGGGACTAACGTTGTATGCGTCTGCGTCTTGTCTTTTTGCATTCGCTTT
CCAAAAAAGAGAGCCATCCGTTCCCCCGCACATTCAACGCCGCGAGTGCGGTTTTTGTCTTTT
TTGAGTGGTAGGACGCTTTTCATGCGCGAACTACGTGGACATTAAGTTCCATTCTCTTTTCCTC
TCCTCTTTCTTCTCTTCTTACTAGTCCTATCCTTTTCCTTCCTTTCTCTCTTCTTCGATGAGACG
TCCTTTCTCCTTTCTTCTCTCTTCTTTTCGACAGCACGAAACCTTGCATTCAAACCCGCCCGGG
GAAGATCCGATCTTGCTGCTGTTCGCAGTCCCAGTAGCGTCCTGTCGGCCGCGCCGTCTCTG
TTGGTGGGCAGCCGCTACACCTGTTATCTGACTGCCGTGCGCGAAAATGACGCCATTTTTGG
GAAAATCGGGGAACTTCATTCTTTAAAAGTATGCGGAGGTTTCCTTTTTCTTCTGTTCGTTTCT
TTTTCTCGGGTTTGATAACCGTGTTCGATGTAAGCACTTTCCGTCTCTCCTCCGTGCTTTGTTC
GACATCGAGACCAGGTGTGCAGATCCTTCGCTTGTTGATCCGGAGACGCGTGTCTCGTAGAA
CCTTTTCATTTTACCACACGGCAGTGCTGAGCACTGCTCTGAGTGCAGCAGGGACGGGTGAA
GTTTCGCTTTAGTAGTGCGTTTCTGCTCTACGGGGCGTTGTCGTGTCTGGGAAGATGGCGGA
CCCAGCTTTCTTGTACAAAGTGGTGGGG 
 
Table S2. Promoter Constructs. Promoter constructs were designed and ordered as 
gBlocks™ Gene Fragments (Invitrogen). The bolded nucleotides (25 bp on each end) 
are the attB1 and attB2 sites used for recombination. In the second and third constructs, 
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the underlined nucleotides indicate either motif or scrambled motif sequences. The ATG 
start codon is bolded and underlined in each construct; translation starts at that location 
in the transcribed mRNA, and the attB2 site is translated in frame with the firefly 
luciferase coding region. 
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Appendix: Glossary of Terms 
AP2  = Apetala 2 
AP2III-3 = indicates the third (3) Apetala 2 transcription factor identified on T.       
   gondii chromosome III 
DHFR-TS = dihydrofolate reductase-thymidylate synthase 
Pru  = Prugniaud strain of T. gondii 
qPCR  = quantitative PCR 
SAGE  = serial analysis of gene expression 
TSS  = transcriptional start site 
 
